Covalent Inhibitors Targeting Mycobacterial Enzymes: Current Status, Challenges and Future Perspectives.

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Microbiology

Background:

• Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a global health emergency despite decades of efforts.
• Increasing drug resistance necessitates novel therapeutic strategies to improve treatment outcomes.
• Enzymatic targets of Mtb are crucial for bacterial survival and represent key targets for drug development.

Purpose of the Study:

• To provide a comprehensive overview of promising covalent inhibitors against Mtb enzymatic targets.
• To highlight recent advancements in the development of novel anti-TB agents.
• To outline future research directions for safer and more effective tuberculosis therapies.

Main Methods:

• Literature review of peer-reviewed articles and scientific databases.
• Critical analysis of covalent inhibitors targeting traditional and emerging Mtb enzymes.
• Synthesis of current progress and identification of future research avenues.

Main Results:

• Identification of several classes of covalent inhibitors with significant potential against Mtb.
• Discussion of the mechanisms of action and structure-activity relationships of these inhibitors.
• Assessment of the challenges and opportunities in translating these inhibitors into clinical applications.

Conclusions:

• Covalent inhibitors represent a promising therapeutic avenue for combating drug-resistant TB.
• Further research is needed to optimize inhibitor design, improve safety profiles, and ensure clinical efficacy.
• A multi-faceted approach combining medicinal chemistry, enzymology, and clinical studies is essential for future progress.